Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04816513 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants
A Phase 1 study of Healthy, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 300
- Enrollment target
- 3
- Study locations
NCT04816513: Completed Phase 1 study of Healthy, sponsored by Janssen Research & Development.
NCT04816513 is a Phase 1 study of Healthy that has completed, run by Janssen Research & Development. The registered enrollment target is 300 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (54% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04816513, a Phase 1 study of Healthy, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 300 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the pharmacokinetic (PK) and bioequivalence (BE) of ustekinumab administered by a single subcutaneous (SC) injection with Device 1 or Device 2 in healthy participants.
Primary Outcome
Cmax is maximum observed serum concentration of ustekinumab.
Conditions Studied
Interventions
- DRUG Ustekinumab
Study Locations (3)
Arizona
- Celerion - Tempe
Nebraska
- Celerion - Lincoln
Utah
- PRA Health Sciences - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2021-04-14 |
| Est. Completion | 2022-01-26 |
| Phase | Phase 1 |
What the finished NCT04816513 record still lists
NCT04816513 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Ustekinumab is the first listed.
NCT04816513 reports a single indexed study location in Arizona, Nebraska, Utah.
Frequently Asked Questions
What is clinical trial NCT04816513 about?
NCT04816513 is a clinical study titled "A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants". The purpose of this study is to evaluate the pharmacokinetic (PK) and bioequivalence (BE) of ustekinumab administered by a single subcutaneous (SC) injection with Device 1 or Device 2 in healthy participants.
What is the current status of trial NCT04816513?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 300 participants. The study started on 2021-04-14. Estimated completion is 2022-01-26.
What conditions does trial NCT04816513 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT04816513?
The interventions under investigation include: Ustekinumab (DRUG).
Who is sponsoring clinical trial NCT04816513?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04816513 being conducted?
This trial has 3 study locations across Arizona, Nebraska, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04816513's enrollment target sits among peer trials
300 77th of 1090 higher than 1,004 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI